Navigation Links
Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
Date:8/31/2012

THE WOODLANDS, Texas, Aug. 31, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the Stifel Nicolaus 2012 Healthcare Conference on Thursday, September 6, at 10:20 a.m. EST in Boston, Massachusetts. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until October 6, 2012.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)... -- Dealmed Medical Supplies, New York City,s ... drugs, vaccines, and specialty medical products and services, announced ... acquire Vantage Medical Supplies, a major distributor of medical ... York . ... practices, will operate under the Dealmed name as of ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... , ... Your World Insurance Services, a long-time Redlands insurance and financial services ... of owner Stacy Boyle to give back to the many charitable organizations that help ... high school,” said Ms. Boyle. “My father passed away without life insurance, and my ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... to Arizona State University student Ashlea Grabau. The $1000 student scholarship is awarded ... 2017 scholarship was awarded to Ashlea Grabau who is a medical student at ...
(Date:9/25/2017)... ... 25, 2017 , ... Sensogram Technologies Inc. today launched an ... watch. VitalBand provides elite level fall detection, automatically calls any number you ... quickly. Plus, it’s a fully functioning smart watch and activity tracker. , ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Coleman Institute, a ... an affiliate in Minneapolis-St. Paul, MN, Dr. Adam Locketz. Dr. Locketz will be ... aftercare planning through his Timewise Medical practice in the twin cities. , ...
(Date:9/25/2017)... ... ... The Renal Support Network (RSN) is proud to announce the launch of ... focused on RSN’s mission to empower people who have kidney disease to become knowledgeable ... Our unique website is loaded with hundreds of exclusive personal stories. These posts are ...
Breaking Medicine News(10 mins):